Lineage Cell Therapeutics, Inc. (LCTX)
| Market Cap | 431.30M |
| Revenue (ttm) | 1.70M |
| Net Income (ttm) | -13.67M |
| Shares Out | 158.73M |
| EPS (ttm) | -0.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $2.66 |
| Previous Close | $2.68 |
| Change ($) | -0.02 |
| Change (%) | -0.75% |
| Day's Open | 2.69 |
| Day's Range | 2.63 - 2.72 |
| Day's Volume | 954,737 |
| 52-Week Range | 0.79 - 3.13 |
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--OPC1 Clinical Update
Lineage Cell Therapeutics Inc (NYSE: LCTX) has granted an exclusive option to Amasa Therapeutics Inc to acquire an exclusive, royalty-bearing license to use its HyStem technology to develop and commerci...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for ...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #CFO--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for ...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for ...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for ...
The company reported great news from a clinical study of its experimental cell therapy for treating eye disease.
Lineage Cell Therapeutics Inc (NYSE: LCTX) has announced that restoration of retinal tissue was observed in two additional patients enrolled in the Phase 1/2a study of its lead product candidate, OpRege...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for ...
Lineage Cell (LCTX) delivered earnings and revenue surprises of -50.00% and -63.46%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for ...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for ser...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for ...
Lineage Cell Therapeutics Inc (NYSE: LCTX) has updated interim results from its ongoing Phase 1/2a study of its lead product candidate, OpRegen, for dry age-related macular degeneration (AMD) with geogr...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet...
Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for ...
5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for ser...
The company announced a license agreement.
Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into a worldwide license and development collaboration agreement with a privately-held Immunomic Therapeutics Inc (ITI) to manufacture and develop ...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #CancerVaccines--VAC/Immunomic Strategic Alliance
ROCKVILLE, Md. & CARLSBAD, Calif.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platfo...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet...
Under a named patient compassionate use approval by the Israeli Ministry of Health, Lineage Cell Therapeutics Inc's (NYSE: LCTX) OpRegen has been used to treat a patient suffering from adult-onset vitel...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for ser...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious med...
Lineage Cell (LCTX) delivered earnings and revenue surprises of 120.00% and -73.57%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...
Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #CIRM--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet m...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #CIRM--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet m...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies to address u...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...
Investors need to pay close attention to Lineage Cell Therapeutics (LCTX) stock based on the movements in the options market lately.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapies for serious...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...
Lineage Cell Therapeutics, Inc. is a clinical-stage biotech company focused on developing therapeutics for degenerative retinal diseases, demyelination-related neurological conditions, and cancer-relate...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #DryAMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapies for seri...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapies for serious...
Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q3 2020 Results - Earnings Call Transcript
About LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute sp... [Read more...]
| Industry Biotechnology | Founded 1990 |
| CEO Brian Culley | Employees 49 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol LCTX |
Financial Performance
In 2020, LCTX's revenue was $1.83 million, a decrease of -48.05% compared to the previous year's $3.52 million. Losses were -$20.65 million, 76.4% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for LCTX stock is "Buy." The 12-month stock price forecast is 5.33, which is an increase of 100.38% from the latest price.